Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
Hospital-acquired pneumonia also called as healthcare associated pneumonia or nosocomial pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report analyzes the market for late stage candidates for treatment of nosocomial pneumonia, and also provides a detailed review of drugs in early stages of clinical trials. The report studies and estimates market for six late stage along with an elucidation of ten early stage candidates for nosocomial pneumonia treatment.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Transparency <strong>Market</strong><br />
Research<br />
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong><br />
<strong>Drugs</strong> <strong>Market</strong> - <strong>Global</strong> <strong>Industry</strong> <strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>,<br />
<strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong> <strong>2014</strong> - <strong>2020</strong><br />
Published Date<br />
<strong>2014</strong>-09-01<br />
74 Page Report<br />
Buy Now<br />
Request Sample<br />
Press Release<br />
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Reveals Six Potential Late Stage (Phase III) C<strong>and</strong>idates, <strong>and</strong> Ten<br />
Late Stage (Phase II, I <strong>and</strong> Preclinical Trials) C<strong>and</strong>idates<br />
Transparency <strong>Market</strong> Research<br />
State Tower,<br />
90, State Street, Suite 700.<br />
Albany, NY 12207<br />
United States<br />
www.transparencymarketresearch.com<br />
sales@transparencymarketresearch.com
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
REPORT DESCRIPTION<br />
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong> <strong>Global</strong> <strong>Industry</strong><br />
<strong>Analysis</strong>, <strong>Size</strong>, <strong>Share</strong>, <strong>Growth</strong>, <strong>Trends</strong> <strong>and</strong> <strong>Forecast</strong> <strong>2014</strong> - <strong>2020</strong><br />
<strong>Hospital</strong>-acquired pneumonia also called as healthcare associated pneumonia or nosocomial<br />
pneumonia is acquired in hospital premises. Unlike community acquired pneumonia hospital<br />
acquired pneumonia is mainly caused due to multidrug resistant microorganisms. The report<br />
analyzes the market for late stage c<strong>and</strong>idates for treatment <strong>of</strong> nosocomial pneumonia, <strong>and</strong> also<br />
provides a detailed review <strong>of</strong> drugs in early stages <strong>of</strong> clinical trials. The report studies <strong>and</strong><br />
estimates market for six late stage along with an elucidation <strong>of</strong> ten early stage c<strong>and</strong>idates for<br />
nosocomial pneumonia treatment.<br />
Phase III c<strong>and</strong>idates include tedizolid phosphate, ceftolozane/tazobactam,<br />
ceftazidime/avibactam, amikacin inhale, plazomicin <strong>and</strong> synflorix vaccine. <strong>Market</strong> for each <strong>of</strong> the<br />
investigational drugs is estimated based on current anti-microbial efficiency, historic market<br />
trend <strong>and</strong> patents <strong>of</strong> drugs from similar class, manufacturing <strong>and</strong> marketing licenses, along with<br />
competition from commercialized <strong>and</strong> pipeline drugs. <strong>Hospital</strong> acquired pneumonia drugs market<br />
for phase III c<strong>and</strong>idates has been estimated from the expected year <strong>of</strong> launch till <strong>2020</strong>. The<br />
hospital acquired pneumonia drugs market report also gives a brief review <strong>of</strong> the various drugs<br />
commercially available for treating hospital acquired pneumonia. Historic market revenue <strong>of</strong><br />
these drugs from 2011 to 2013 has also been included. <strong>Market</strong> forecast mainly rests on a<br />
detailed event impact analysis, which considers historic as well as anticipated events which<br />
impact the market in varying degrees.<br />
Browse the full <strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Report at :<br />
http://www.transparencymarketresearch.com/hospital-acquired-pneumoniadrugs.html<br />
Transparency <strong>Market</strong> Research<br />
2
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
<strong>Global</strong> market for hospital acquired pneumonia drugs is mainly driven by the increasing<br />
prevalence <strong>of</strong> nosocomial infections across the globe. To illustrate this fact, the report includes a<br />
statistical comparison <strong>of</strong> the prevalence <strong>of</strong> nosocomial infections in various developed <strong>and</strong><br />
developing countries. Geographical trend <strong>of</strong> hospital acquired pneumonia drugs market, is<br />
explains with a brief regulatory approval process, along with expected time frame for drug<br />
launch in various countries. These trends have been explained for geographical regions including<br />
North America, Europe, Asia Pacific <strong>and</strong> Rest <strong>of</strong> the World.<br />
To gain a complete market underst<strong>and</strong>ing, Porters Five Force’s analysis, <strong>and</strong> value chain analysis<br />
has also been included in the hospital acquired pneumonia drugs market report. The report also<br />
explains key market drivers, restraints, opportunities in the hospital acquired pneumonia drugs<br />
market. Diagnosis, treatment, <strong>and</strong> epidemiology <strong>of</strong> hospital acquired pneumonia gives a clinical<br />
overview <strong>of</strong> the disease <strong>and</strong> current modes <strong>of</strong> disease management. Relevant recommendations<br />
have been suggested for designing successful market strategies for competing in the market.<br />
Browse the full <strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
press release at :<br />
http://www.transparencymarketresearch.com/pressrelease/hospital-acquiredpneumonia-drugs.htm<br />
<strong>Hospital</strong> acquired pneumonia drugs market report also includes company pr<strong>of</strong>iles <strong>of</strong> key market<br />
players. These include Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist<br />
Pharmaceuticals, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Ltd., San<strong>of</strong>i, GlaxoSmithKline,<br />
Inc., <strong>and</strong> Valneva SE. All <strong>of</strong> these players are pr<strong>of</strong>iled considering company overview, financial<br />
overview, product portfolio, business strategies, <strong>and</strong> recent developments.<br />
Get Free Sample Report <strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong><br />
<strong>Drugs</strong> <strong>Market</strong> :<br />
Transparency <strong>Market</strong> Research<br />
3
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
http://www.transparencymarketresearch.com/sample/sample.php?<br />
flag=S&rep_id=1881<br />
The research methodology was based on primary as well as secondary research. Interviews <strong>and</strong><br />
discussions with a wide range <strong>of</strong> key industry participants <strong>and</strong> opinion leaders revealed real time<br />
market scenario. This primary research represented the bulk <strong>of</strong> the research efforts, which was<br />
further supplemented by extensive secondary research. A review <strong>of</strong> key players’ product<br />
literature, annual reports, <strong>and</strong> press releases supports the market forecast analysis. The 74 page<br />
report explains various market dynamics in 4 tables <strong>and</strong> 17 figures <strong>and</strong> charts.<br />
TABLE OF CONTENT<br />
Chapter 1 Preface<br />
1.1 Report Description<br />
1.2 <strong>Market</strong> Segmentation<br />
1.3 Research Methodology<br />
1.3.1 Secondary Research<br />
1.3.2 Primary Research<br />
1.4 List <strong>of</strong> Abbreviations<br />
1.5 Assumptions<br />
Chapter 2 Executive Summary<br />
2.1.1 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> Phase III C<strong>and</strong>idates, <strong>Market</strong> <strong>Share</strong>, <strong>2020</strong> (Value %)<br />
Transparency <strong>Market</strong> Research<br />
4
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Chapter 3 <strong>Market</strong> overview<br />
3.1 Introduction<br />
3.1.1 Types <strong>of</strong> Nosocomial <strong>Pneumonia</strong><br />
3.1.1.1 Bacterial pneumonia<br />
3.1.1.2 Viral pneumonia<br />
3.1.2 Epidemiology <strong>of</strong> hospital acquired pneumonia<br />
3.1.3 Diagnosis <strong>of</strong> hospital acquired pneumonia<br />
3.1.4 Treatment <strong>of</strong> hospital acquired pneumonia<br />
3.2 <strong>Market</strong> Dynamics<br />
3.2.1 <strong>Market</strong> Drivers<br />
3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances <strong>of</strong> hospital<br />
acquired infections<br />
3.2.1.2 Inefficient sterilization <strong>and</strong> unhygienic conditions in low <strong>and</strong> middle income countries<br />
increasing prevalence <strong>of</strong> hospital acquired infections<br />
3.2.1.2.1 Prevalence <strong>of</strong> hospital acquired infections in developed <strong>and</strong> developing countries<br />
3.2.2 <strong>Market</strong> Restraints<br />
3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections<br />
3.2.3 <strong>Market</strong> Opportunities<br />
3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market<br />
pneumonia<br />
3.2.3.2 Potential for research in vaccine development for causative agents other than S.<br />
Transparency <strong>Market</strong> Research<br />
5
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.3 Event Impact <strong>Analysis</strong><br />
3.3.1 Event Impact <strong>Analysis</strong>: <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Market</strong><br />
3.4 Value Chain <strong>Analysis</strong><br />
3.4.1 Value Chain <strong>Analysis</strong><br />
3.5 Porter’s Five Forces <strong>Analysis</strong> for the <strong>Global</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
3.5.1 Bargaining Power <strong>of</strong> Suppliers<br />
3.5.2 Porter’s Five Forces <strong>Analysis</strong>: <strong>Global</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Market</strong><br />
3.5.3 Bargaining Power <strong>of</strong> Buyers<br />
3.5.4 Threat <strong>of</strong> Substitutes<br />
3.5.5 Threat <strong>of</strong> New Entrants<br />
3.5.6 Competitive Rivalry<br />
3.6 <strong>Market</strong> <strong>Analysis</strong> <strong>of</strong> Major <strong>Drugs</strong> <strong>and</strong> Vaccines for <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong><br />
Million)<br />
3.6.1 Revenue trend <strong>of</strong> major br<strong>and</strong>ed drugs <strong>and</strong> vaccines in nosocomial pneumonia market (USD<br />
Chapter 4 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong>, <strong>Pipeline</strong> <strong>Analysis</strong><br />
4.1 Introduction<br />
4.2 Late Stage (Phase III)<br />
4.2.1 Tedizolid phosphate<br />
4.2.1.1 <strong>Global</strong> Tedizolid Phosphate <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD million)<br />
Transparency <strong>Market</strong> Research<br />
6
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.2.2 Ceftolozane/Tazobactam<br />
4.2.2.1 <strong>Global</strong> Ceftolozane/Tazobactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD million)<br />
4.2.3 Ceftazidime/Avibactum<br />
4.2.3.1 <strong>Global</strong> Ceftazidime/Avibactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.4 Amikacin Inhale<br />
4.2.4.1 <strong>Global</strong> Amikacin Inhale <strong>Market</strong> Revenue, 2016 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.5 Plazomicin<br />
4.2.5.1 <strong>Global</strong> Plazomicin <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.2.6 Synflorix Vaccine<br />
4.2.6.1 <strong>Global</strong> Synflorix <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
4.3 Early Stage (Phase I <strong>and</strong> II)<br />
4.3.1 BAL30072<br />
4.3.2 MEDI4893<br />
4.3.3 AR-301 or KBSA301<br />
4.3.4 AR-101 (or KBPA101) <strong>and</strong> AR-104 (or KBPA104)<br />
4.3.5 AR-201 (or KBRV201)<br />
4.3.6 AR-401 (or KBAB401)<br />
4.3.7 ME1100<br />
4.3.8 GSK 2189242A<br />
4.3.9 V114<br />
Transparency <strong>Market</strong> Research<br />
7
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
4.3.10 IC43<br />
Chapter 5 <strong>Global</strong> <strong>Pipeline</strong> Review <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong>, by Geography<br />
5.1 Introduction<br />
5.2 North America<br />
5.3 Europe<br />
5.4 Asia Pacific<br />
5.5 Rest <strong>of</strong> the World<br />
Chapter 6 Recommendations<br />
6.1 Research <strong>and</strong> development for biological drugs<br />
6.2 Mergers, acquisitions <strong>and</strong> strategic agreements<br />
Chapter 7 Company Pr<strong>of</strong>iles<br />
7.1 Achaogen, Inc.<br />
7.1.1 Company Overview<br />
7.1.2 Financial Overview<br />
7.1.3 Product Portfolio<br />
7.1.4 Business Strategies<br />
7.1.5 Recent Developments<br />
Transparency <strong>Market</strong> Research<br />
8
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
7.2 Aridis Pharmaceuticals<br />
7.2.1 Company Overview<br />
7.2.2 Financial Overview<br />
7.2.3 Product Portfolio<br />
7.2.4 Business Strategies<br />
7.2.5 Recent Developments<br />
7.3 AstraZeneca plc<br />
7.3.1 Company Pr<strong>of</strong>ile<br />
7.3.2 Financial Overview<br />
7.3.3 Product Portfolio<br />
7.3.4 Business Strategies<br />
7.3.5 Recent Developments<br />
7.4 Cubist Pharmaceuticals, Inc.<br />
7.4.1 Company Overview<br />
7.4.2 Financial Overview<br />
7.4.3 Product Portfolio<br />
7.4.4 Business Strategies<br />
7.5 Meiji Seika Pharma Co. Ltd.<br />
7.5.1 Company Overview<br />
7.5.2 Financial Overview<br />
Transparency <strong>Market</strong> Research<br />
9
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
7.5.3 Product Portfolio<br />
7.5.4 Business Strategies<br />
7.5.5 Recent Developments<br />
7.6 Merck & Co. Inc.<br />
7.6.1 Company Overview<br />
7.6.2 Financial Overview<br />
7.6.3 Product Portfolio<br />
7.6.4 Business Strategies<br />
7.6.5 Recent Developments<br />
7.7 San<strong>of</strong>i<br />
7.7.1 Company Overview<br />
7.7.2 Financial Overview<br />
7.7.3 Product Portfolio<br />
7.7.4 Business Strategies<br />
7.7.5 Recent Developments<br />
7.8 GlaxoSmithKline, Inc.<br />
7.8.1 Company Overview<br />
7.8.2 Financial Overview<br />
7.8.3 Product Portfolio<br />
7.8.4 Business Strategies<br />
Transparency <strong>Market</strong> Research<br />
10
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
7.8.5 Recent Developments<br />
7.9 Valneva SE<br />
7.9.1 Company Overview<br />
7.9.2 Financial Overview<br />
7.9.3 Product Portfolio<br />
7.9.4 Business Strategies<br />
7.9.5 Recent Developments<br />
List <strong>of</strong> Figures<br />
FIG. 1 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong>: Drug <strong>Pipeline</strong><br />
FIG. 2 <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> Phase III C<strong>and</strong>idates, <strong>Market</strong> <strong>Share</strong>, <strong>2020</strong> (Value %)<br />
FIG. 3 Value Chain <strong>Analysis</strong><br />
FIG. 4 Porter’s Five Forces <strong>Analysis</strong>: <strong>Global</strong> <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Market</strong><br />
FIG. 5 Revenue trend <strong>of</strong> major br<strong>and</strong>ed drugs <strong>and</strong> vaccines in nosocomial pneumonia market (USD Million)<br />
FIG. 6 <strong>Global</strong> Tedizolid Phosphate <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 7 <strong>Global</strong> Ceftolozane/Tazobactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD million)<br />
FIG. 8 <strong>Global</strong> Ceftazidime/Avibactam <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 9 <strong>Global</strong> Amikacin Inhale <strong>Market</strong> Revenue, 2016 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 10 <strong>Global</strong> Plazomicin <strong>Market</strong> Revenue, 2017 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
FIG. 11 <strong>Global</strong> Synflorix <strong>Market</strong> Revenue, 2012 <strong>–</strong> <strong>2020</strong> (USD Million)<br />
Transparency <strong>Market</strong> Research<br />
11
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 16 San<strong>of</strong>i: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 <strong>–</strong> 2013 (USD Million)<br />
List <strong>of</strong> Tables<br />
TABLE 1 Nosocomial <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>and</strong> Vaccines, <strong>Market</strong> Snapshot<br />
TABLE 2 Investigational C<strong>and</strong>idates for Nosocomial <strong>Pneumonia</strong> Treatment<br />
TABLE 3 Prevalence <strong>of</strong> <strong>Hospital</strong> <strong>Acquired</strong> Infections in Developed <strong>and</strong> Developing Countries<br />
TABLE 4 Event Impact <strong>Analysis</strong>, <strong>Hospital</strong> <strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Market</strong><br />
Browse All Pharmaceutical <strong>Market</strong> Research Reports @<br />
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html<br />
About Us<br />
Transparency <strong>Market</strong> Research is a market intelligence company providing global business information<br />
reports <strong>and</strong> services. Our exclusive blend <strong>of</strong> quantitative forecasting <strong>and</strong> trends analysis provides forwardlooking<br />
insight for thous<strong>and</strong>s <strong>of</strong> decision makers.<br />
We are privileged with highly experienced team <strong>of</strong> Analysts, Researchers <strong>and</strong> Consultants, who use<br />
proprietary data sources <strong>and</strong> various tools <strong>and</strong> techniques to gather, <strong>and</strong> analyze information. Our<br />
business <strong>of</strong>ferings represent the latest <strong>and</strong> the most reliable information indispensable for businesses to<br />
sustain a competitive edge.<br />
Transparency <strong>Market</strong> Research<br />
12
<strong>Pipeline</strong> <strong>Analysis</strong> <strong>of</strong> <strong>Hospital</strong><br />
<strong>Acquired</strong> <strong>Pneumonia</strong> <strong>Drugs</strong> <strong>Market</strong><br />
Contact<br />
Transparency <strong>Market</strong> Research<br />
90 State Street,<br />
Suite 700,<br />
Albany<br />
NY - 12207<br />
United States<br />
Tel: +1-518-618-1030<br />
USA - Canada Toll Free 866-552-3453<br />
Email: sales@transparencymarketresearch.com<br />
Website: http://www.transparencymarketresearch.com/<br />
Browse The <strong>Market</strong> Research Blog :<br />
http://research<strong>and</strong>reports.wordpress.com/ http://www.transparencymarketresearch.com<br />
Transparency <strong>Market</strong> Research<br />
13
Change language